The purpose of this First-in-Human, open-label, dose escalation study is to assess the initial safety and efficacy profile of ANV419 intravenous infusion in patients with advanced solid tumours and multiple myeloma. It will evaluate the safety and tolerability of ANV419 alone and, the safest and best dose of ANV419 when used alone.
The purpose of this study is to test the safety and efficacy of ANV419 (single agent) in patients with relapsed/refractory advanced solid tumors and multiple myeloma.